Beta Bionics (NASDAQ:BBNX) Stock Picked Up by Analysts at Jefferies Financial Group

Posted by Stanley Muller on Oct 14th, 2026

Analysts at Jefferies Financial Group began coverage on shares of Beta Bionics (NASDAQ:BBNX – Get Free Report) in a research note issued to investors on Monday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $30.00 price target on the stock. Jefferies Financial Group’s price objective would indicate a potential upside of 69.59% from the stock’s previous close.

A number of other brokerages have also issued reports on BBNX. Barclays began coverage on shares of Beta Bionics in a research note on Tuesday, October 6th. They set an “overweight” rating and a $30.00 target price for the company. Robert W. Baird boosted their price target on shares of Beta Bionics from $14.00 to $16.00 and gave the company a “neutral” rating in a report on Tuesday, September 15th. Truist Financial upped their price target on shares of Beta Bionics from $23.00 to $28.00 and gave the stock a “buy” rating in a research note on Thursday, September 24th. The Goldman Sachs Group increased their price objective on Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Finally, UBS Group reiterated a “buy” rating and set a $25.00 price objective on shares of Beta Bionics in a report on Tuesday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Beta Bionics presently has a consensus rating of “Moderate Buy” and an average target price of $24.00.

View Our Latest Stock Report on BBNX

Beta Bionics Price Performance

NASDAQ BBNX opened at $17.69 on Monday. The company has a 50 day simple moving average of $18.91 and a 200-day simple moving average of $15.10. Beta Bionics has a 52-week low of $8.80 and a 52-week high of $32.71.

Beta Bionics (NASDAQ:BBNX – Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. The firm had revenue of $32.01 million for the quarter. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. Research analysts predict that Beta Bionics will post -2.02 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Stephen Feider sold 6,675 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total value of $127,559.25. Following the transaction, the chief financial officer owned 159,378 shares in the company, valued at approximately $3,045,713.58. This represents a 4.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mark Hopman sold 30,779 shares of the stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $20.13, for a total value of $619,581.27. Following the completion of the transaction, the insider owned 56,479 shares in the company, valued at $1,136,922.27. This represents a 35.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 97,697 shares of company stock worth $1,907,034 in the last quarter. Corporate insiders own 5.30% of the company’s stock.

Institutional Trading of Beta Bionics

Several large investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd increased its position in Beta Bionics by 1,075.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock worth $61,000 after buying an additional 1,818 shares during the last quarter. Legal & General Group Plc bought a new position in Beta Bionics during the second quarter valued at about $62,000. The Manufacturers Life Insurance Company bought a new position in Beta Bionics during the second quarter valued at about $172,000. Ieq Capital LLC acquired a new stake in shares of Beta Bionics in the second quarter worth about $229,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Beta Bionics in the second quarter worth about $264,000.

Key Stories Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

Positive Sentiment: Jefferies initiated coverage of Beta Bionics with a “Buy” rating and a $30 price target, implying substantial upside from recent trading levels. The bullish view provides some support for the stock and reflects optimism about the company’s long-term commercial potential. Beta Bionics upgraded to Strong-Buy at Jefferies
Neutral Sentiment: Multiple law firms, including Rosen, Pomerantz, Kaplan Fox, Glancy Prongay and others, reminded investors that November 3, 2026 is the deadline to seek lead-plaintiff status in a securities class action covering purchases from July 30, 2025 through February 24, 2026. These notices primarily solicit participation and do not establish that Beta Bionics is liable. Rosen investor deadline notice
Negative Sentiment: The lawsuit activity is negative for investor sentiment because plaintiffs allege Beta Bionics misled investors about the iLet system’s safety, efficacy and commercial performance. One complaint alleges the company’s SEC disclosures characterized FDA findings as quality-system “non-conformities” while omitting hundreds of unreported iLet complaints involving potentially life-threatening hypoglycemia. The legal campaign follows a reported stock decline of more than 37% after revelations concerning FDA compliance and device safety. The allegations remain unproven, but the litigation creates regulatory, reputational and potential financial risks. BBNX medical-device safety lawsuit report

About Beta Bionics

(Get Free Report)

Beta Bionics, Inc is a medical technology company focused on developing and commercializing automated insulin delivery systems for people with insulin-requiring diabetes. Its lead product is the iLet Bionic Pancreas, an insulin pump system designed to automate much of the insulin-dosing process and reduce the daily burden associated with diabetes management.

The iLet Bionic Pancreas uses continuous glucose monitoring data and the company’s dosing algorithms to deliver insulin. Unlike conventional insulin pumps that generally require users to calculate meal doses, the system is designed to simplify mealtime dosing by using a person’s body weight and meal announcements as key inputs.